NeurogesX (NGSX) Higher On FDA Approval of Qutenza
More News related to NGSX
- NeurogesX to Present at BIO CEO & Investor Conference
- NeurogesX Announces Management Team Promotions
- NeurogesX to Present at J.P. Morgan Health Care Conference
- NeurogesX (NGSX) Higher On FDA Approval of Qutenza
- NeurogesX (NGSX) Posts Q3 Loss of 38C, Wider than Expected
More News related to FDA
- Genzyme (GENZ) and Isis (ISIS) Said Mipomersen Phase 3 Study Meets Primary Endpoint
- Alexza Pharmaceuticals (ALXA) Announces Collaboration With Biovail (BVF), $40M Upfront
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- XenoPort (XNPT) Said FDA Moves PDUFA Date Due to February 11
- Dendreon (DNDN) CEO Says Provenge Salesforce Will Be 125 People, Sees Full Manufacturing Ability by Mid-2011
After the close, NeurogesX, Inc. (Nasdaq: NGSX) announced today that the FDA has approved Qutenza 8% patch, the first and only product containing prescription strength capsaicin, for the management of neuropathic pain due to postherpetic neuralgia (PHN), the nerve pain which can follow shingles.
This is the first product from NeurogesX to be approved by the FDA.
Qutenza works by targeting certain pain nerves in the area of skin where pain is being experienced.
Shares of NeurogesX are up 9 percent to $8.99 before the market opens.
Related Categories
FDAMomentum Movers
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
